Table 1.
Group | Rats | Type of HA | Rats per group for TVT (ROTEM) | Treatment (dose, mg kg−1) | Design |
---|---|---|---|---|---|
1 | FVIII−/− | Congenital | 10 (5) | Vehicle | S |
2 | FVIII−/− | Congenital | 10 (5) | TXA (350) | S and B |
3 | FVIII−/− | Congenital | 10 (5) | rFVIIa (0.5 ~ ED50) | S and B |
4 | FVIII−/− | Congenital | 10 (5) | rFVIIa (0.5 ~ ED50) + TXA (350) | S and B |
5 | WT | - | 11 (5) | Vehicle | S |
B, blinded; ED50, median effective dose; HA, hemophilia A; rFVIIa, activated recombinant factor VII; S, stratified; TXA, tranexamic acid; WT, wild type. All rats were subjected to the TVT bleeding assay. Following the TVT bleeding study, half of the rats had blood drawn from a carotid artery catheter for ROTEM analyses. Data from the study are shown in Figs 1 and 2.